Table 3 Univariate analysis of tumour recrudesce after surgery in included individuals
Variations | Cases (n = 160) | 1-year DFS rate (%) | 3-year DFS rate (%) | χ2 Value | P Value |
|---|---|---|---|---|---|
Sex | Â | Â | Â | 0.660 | 0.416 |
 Male | 89 | 47.3 | 20.4 |  |  |
 Female | 71 | 64.5 | 25.2 |  |  |
Age (years) | Â | Â | Â | 0.015 | 0.904 |
  ≤ 60 | 60 | 59.5 | 18.5 |  |  |
  > 60 | 100 | 52.3 | 25.1 |  |  |
Diabetes | Â | Â | Â | 0.045 | 0.833 |
 Yes | 53 | 49.4 | 22.2 |  |  |
 No | 107 | 57.7 | 22.8 |  |  |
Jaundice reduction treatment before surgery | Â | Â | Â | 0.000 | 0.994 |
 Yes | 36 | 47.2 | 18.3 |  |  |
 No | 124 | 57.3 | 22.7 |  |  |
Preoperative total bilirubin (μmol/L) |  |  |  | 0.094 | 0.760 |
  ≤ 21 | 70 | 57.4 | 23.9 |  |  |
  > 21 | 90 | 53.3 | 20.2 |  |  |
Preoperative carbohydrate antigen 19–9 (U/ml) |  |  |  | 0.044 | 0.834 |
  ≤ 37 | 40 | 52.5 | 24.2 |  |  |
  > 37 | 120 | 55.9 | 20.9 |  |  |
Preoperative albumin (g/L) | Â | Â | Â | 3.574 | 0.059 |
  ≤ 40 | 119 | 51.5 | 18.7 |  |  |
  > 40 | 41 | 65.2 | 30.7 |  |  |
Postoperative 4Â weeks albumin (g/L) | Â | Â | Â | 3.367 | 0.067 |
  ≤ 40 | 124 | 50.7 | 19.7 |  |  |
  > 40 | 36 | 69.4 | 32.2 |  |  |
Pre-operative BMI | Â | Â | Â | 5.000 | 0.082 |
  < 18.5 | 11 | 72.7 | 43.6 |  |  |
 18.5–23.9 | 87 | 49.3 | 19.3 |  |  |
  ≥ 24.0 | 62 | 59.7 | 20.4 |  |  |
Postoperative 4Â weeks BMI | Â | Â | Â | 2.835 | 0.242 |
  < 18.5 | 13 | 61.5 | 34.6 |  |  |
 18.5–23.9 | 96 | 50.9 | 18.3 |  |  |
  ≥ 24.0 | 51 | 60.8 | 22.3 |  |  |
Preoperative LDL-c (mmol/L) | Â | Â | Â | 1.085 | 0.297 |
  ≤ 2.375 | 64 | 51.1 | 22.3 |  |  |
  > 2.375 | 96 | 57.6 | 24.2 |  |  |
Postoperative 3Â days LDL-c (mmol/L) | Â | Â | Â | 0.515 | 0.473 |
  ≤ 1.460 | 61 | 49.5 | 20.8 |  |  |
  > 1.460 | 99 | 57.3 | 23.9 |  |  |
Postoperative 1Â week LDL-c (mmol/L) | Â | Â | Â | 1.206 | 0.272 |
  ≤ 1.785 | 71 | 42.3 | 17.7 |  |  |
  > 1.785 | 89 | 64.9 | 23.4 |  |  |
Postoperative 4Â weeks LDL-c (mmol/L) | Â | Â | Â | 7.903 | 0.005 |
  ≤ 1.515 | 47 | 40.4 | 11.7 |  |  |
  > 1.515 | 113 | 60.2 | 26.2 |  |  |
Postoperative 8Â weeks LDL-c (mmol/L) | Â | Â | Â | 2.519 | 0.113 |
  ≤ 1.505 | 55 | 46.3 | 12.3 |  |  |
  > 1.505 | 105 | 55.6 | 18.4 |  |  |
Operation time (hours) | Â | Â | Â | 1.373 | 0.241 |
  ≤ 8 | 58 | 57.5 | 33.7 |  |  |
  > 8 | 102 | 53.5 | 18.1 |  |  |
Intraoperative hemorrhage volume (ml) | Â | Â | Â | 1.058 | 0.304 |
  ≤ 800 | 90 | 58.9 | 25.2 |  |  |
  > 800 | 70 | 49.9 | 19.0 |  |  |
Intraoperative transfusion | Â | Â | Â | 1.829 | 0.176 |
 Yes | 62 | 47.4 | 16.0 |  |  |
 No | 98 | 59.8 | 27.5 |  |  |
Tumour differentiation degree | Â | Â | Â | 18.268 | 0.000 |
 Low | 47 | 29.8 | 7.2 |  |  |
 Moderate/High | 113 | 65.7 | 29.1 |  |  |
Tumour size (cm) | Â | Â | Â | 7.440 | 0.006 |
  ≤ 4 | 112 | 58.5 | 27.5 |  |  |
  > 4 | 48 | 44.3 | 6.6 |  |  |
Lymphatic metastasis | Â | Â | Â | 12.105 | 0.001 |
 Yes | 100 | 44.6 | 14.8 |  |  |
 No | 60 | 72.7 | 35.5 |  |  |
Portal venous system invasion | Â | Â | Â | 1.889 | 0.169 |
 Yes | 70 | 51.4 | 17.3 |  |  |
 No | 90 | 57.8 | 26.9 |  |  |
Postoperative complications | Â | Â | Â | 0.793 | 0.373 |
 Yes | 48 | 44.8 | 21.5 |  |  |
 No | 112 | 59.4 | 22.9 |  |  |
Postoperative chemotherapy | Â | Â | Â | 0.005 | 0.945 |
 Yes | 86 | 59.8 | 20.0 |  |  |
 No | 74 | 49.4 | 23.2 |  |  |